Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
|Articles|April 27, 2003
Visual imaging platform offers specialized procedures
The Visera Digital Visual Imaging and Information platform from Olympusallows the physician to specialize each procedure while maintaining standardizationon the platform, creating greater operating efficiency for operating roomstaff and surgeons. The system can be upgraded to match the changing anddiverse needs of a facility's medical staff by adding build-on-demand moduleseven after the unit has been purchased and installed.
Advertisement
Advertisement
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
3
Experts review evidence on testosterone and prostate cancer
4
Carotuximab plus apalutamide shows interim PFS benefit in mCRPC
5